GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer

著者: Jun Liang, Jennifer E. Klomp, Robert A. Blake, Jae H. Chang, Stephen Daly, Antonio G. DiPasquale, Lori S. Friedman, Thomas Gelzleichter, Matthew Gill, Jennifer M. Giltnane, Simon Goodacre, Jane Guan, Steven J. Hartman, Ellen Ingalla, Lorn Kategaya, James R. Kiefer, Tracy Kleinheinz, Sharada S. Labadie, Tommy Lai, Jun Li, Jiangpeng Liao, Zhiguo Liu, Vidhi Mody, Neville McLean, Ciara Metcalfe, Michelle Nannini, Jason Oeh, Martin O’Rourke, Daniel F. Ortwine, Yingqing Ran, Nicholas C. Ray, Fabien Roussel, Amy Sambrone, Deepak Sampath, Leah Schutt, Maia Vinogradova, John Wai, Tao Wang, Ingrid E. Wertz, Jonathan White, Siew Kuen Yeap, Amy Young, Birong Zhang, Xiaoping Zheng, Wei Zhou, Yu Zhong, Xiaojing Wang - Journal of Medicinal Chemistry 2021 被引用: 135

is being evaluated in Phase III clinical trials.